Table 1. SUMMARY OF COMPARATIVE STUDIES IN PATIENTS.
| CLINICAL CONDITION | DRUG | BA RESULT | METHOD | REF. |
|---|---|---|---|---|
| LIVER DISEASE | ||||
| Verapamil | P 52%, H 22% | SI | 16 | |
| KIDNEY DISEASE | ||||
| Cibenzoline | P 90%, H 83% | SI | 17 | |
| Nitrendipine | 21% | SI | 18 | |
| 23% | SI | 19 | ||
| HEART DISEASE | ||||
| NAPA | P 78% | SI | 20 | |
| H 92% | SI | 2 | ||
| EPILEPSY | ||||
| Phenytoin | P 100%, H 100% | SI | 21 | |
| ADDICTS | ||||
| Methadone | Addict 79% | SI | 22 | |
| Cancer 50%? | Response | 23 | ||
| ELDERLY | ||||
| Verapamil | S 14% R 38% |
SI | 24 | |
| S 16% R 38% |
Conventional | 25 | ||
| Propafenone | Extensive 30% Poor 83% |
SI | 26 | |
| Extensive 30% Poor 81% |
SI | 27 | ||
| NEONATES | ||||
| Phenytoin | 50 - 100% | SI | 28 | |
| No comparator | ||||
| PREGNANCY | ||||
| Ca-carbonate | Non-EC 22% EC 3% |
SI | 29 |
* Abbreviations: H = healthy subjects, P = patients, BA-bioavailability, Ref.-reference number, S&R-enantiomers, Extensive and Poor metabolizers, EC-enteric coated, SI-stable isotope method. Healthy subject results are listed on the same line for concurrent studies and on the line below for studies done prior to or after the patient studies.